GB201223223D0 - Inflammatory bowel disease - Google Patents
Inflammatory bowel diseaseInfo
- Publication number
- GB201223223D0 GB201223223D0 GBGB1223223.7A GB201223223A GB201223223D0 GB 201223223 D0 GB201223223 D0 GB 201223223D0 GB 201223223 A GB201223223 A GB 201223223A GB 201223223 D0 GB201223223 D0 GB 201223223D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- inflammatory bowel
- bowel disease
- disease
- inflammatory
- bowel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1223223.7A GB201223223D0 (en) | 2012-12-21 | 2012-12-21 | Inflammatory bowel disease |
| US14/653,750 US10012654B2 (en) | 2012-12-21 | 2013-12-23 | Biomarkers in inflammatory bowel disease |
| ES13818771T ES2915725T3 (en) | 2012-12-21 | 2013-12-23 | Biomarkers in inflammatory bowel disease |
| EP13818771.1A EP2936162B1 (en) | 2012-12-21 | 2013-12-23 | Biomarkers in inflammatory bowel disease |
| PCT/GB2013/053418 WO2014096873A1 (en) | 2012-12-21 | 2013-12-23 | Biomarkers in inflammatory bowel disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1223223.7A GB201223223D0 (en) | 2012-12-21 | 2012-12-21 | Inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201223223D0 true GB201223223D0 (en) | 2013-02-06 |
Family
ID=47682445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1223223.7A Ceased GB201223223D0 (en) | 2012-12-21 | 2012-12-21 | Inflammatory bowel disease |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10012654B2 (en) |
| EP (1) | EP2936162B1 (en) |
| ES (1) | ES2915725T3 (en) |
| GB (1) | GB201223223D0 (en) |
| WO (1) | WO2014096873A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU92982B1 (en) * | 2016-02-25 | 2017-09-08 | Univ Hamburg Eppendorf Uke | IL-22BP as biomarker in anti-TNF-alpha-treatments |
| WO2017144603A1 (en) * | 2016-02-25 | 2017-08-31 | Universitätsklinikum Hamburg-Eppendorf | Il-22bp as biomarker in anti-tnf-alpha-treatments |
| EP3963334A1 (en) * | 2019-05-02 | 2022-03-09 | University of Limerick | A method of determining the probability of inflammatory bowel disease in a subject being ulcerative colitis or crohn's disease |
| WO2022199682A1 (en) * | 2021-03-26 | 2022-09-29 | 广州市妇女儿童医疗中心 | Marker for diagnosis or early diagnosis of hirschsprung's disease and application thereof |
| GB202115242D0 (en) | 2021-10-22 | 2021-12-08 | Univ I Tromsoe Norges Arktiske Univ | Methods of predicting stable remission in ulcerative colitis |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0313864A (en) | 1989-06-12 | 1991-01-22 | Teijin Ltd | Measuring method of tnf-alpha, kit and method of diagnosis |
| CA2190586A1 (en) | 1994-05-17 | 1995-11-23 | Scott E. Plevy | Methods of screening for crohn's disease using tnf microsatellite alleles |
| WO1997039146A1 (en) | 1996-04-12 | 1997-10-23 | Cedars-Sinai Medical Center | Methods of identifying and diagnosing inflammatory bowel disease |
| US6183951B1 (en) | 1997-04-11 | 2001-02-06 | Prometheus Laboratories, Inc. | Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy |
| GB0124315D0 (en) | 2001-10-10 | 2001-11-28 | Oxagen Ltd | Inflammatory bowel disease |
| WO2005016954A2 (en) | 2003-08-14 | 2005-02-24 | Boston Medical Center Corporation | Immunologic activity measure(s) for t “helper” on-associated conditions |
| ATE491953T1 (en) | 2003-09-15 | 2011-01-15 | Oklahoma Med Res Found | METHOD OF USING CYTOKINT TESTING FOR THE DIAGNOSIS, TREATMENT AND ASSESSMENT OF ANKYLOID SPONDYLITIS |
| RU2258223C2 (en) | 2003-10-31 | 2005-08-10 | Лазебник Леонид Борисович | Method for detecting indications for immunological correction of crohn's disease and inspecific ulcerous colitis |
| US20060205012A1 (en) | 2004-12-09 | 2006-09-14 | Meso Scale Technologies, Llc | Diagnostic test |
| EA201000131A1 (en) | 2007-08-02 | 2010-08-30 | АйЭсЭс ИММЬЮН СИСТЕМ СТИМУЛЕЙШН АБ | DIAGNOSTIC, DETERMINATION OF THE STAGE AND MONITORING OF THE INFLAMMATORY DISEASE OF THE INTESTINE |
| AU2009320061A1 (en) | 2008-11-03 | 2010-06-03 | Merck Sharp & Dohme Corp. | Inflammatory bowel disease biomarkers and related methods of treatment |
| US20110229471A1 (en) * | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| CA2750531A1 (en) | 2009-01-23 | 2010-07-29 | Drexel University | Apparatus and methods for detecting inflammation using quantum dots |
| WO2010103350A1 (en) | 2009-03-10 | 2010-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting the responsiveness to an anti-tnf alpha antibody treatment |
| US10041948B2 (en) | 2010-10-12 | 2018-08-07 | Mayo Foundation For Medical Education And Research | Materials and methods for determining cancer risk |
| AU2012346861A1 (en) | 2011-11-30 | 2014-06-19 | AbbVie Deutschland GmbH & Co. KG | Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor |
-
2012
- 2012-12-21 GB GBGB1223223.7A patent/GB201223223D0/en not_active Ceased
-
2013
- 2013-12-23 US US14/653,750 patent/US10012654B2/en active Active
- 2013-12-23 ES ES13818771T patent/ES2915725T3/en active Active
- 2013-12-23 EP EP13818771.1A patent/EP2936162B1/en active Active
- 2013-12-23 WO PCT/GB2013/053418 patent/WO2014096873A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20150323546A1 (en) | 2015-11-12 |
| WO2014096873A1 (en) | 2014-06-26 |
| US10012654B2 (en) | 2018-07-03 |
| ES2915725T3 (en) | 2022-06-24 |
| EP2936162B1 (en) | 2022-04-20 |
| EP2936162A1 (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201222205D0 (en) | Early entry | |
| GB201201727D0 (en) | Indicating locations | |
| GB201304182D0 (en) | No details | |
| EP2815691A4 (en) | Endoscope | |
| EP2692278A4 (en) | Endoscope | |
| EP2837320A4 (en) | Endoscope | |
| EP2835093A4 (en) | Endoscope | |
| IL237856A0 (en) | Antigens associated with inflammatory bowel disease | |
| EP2868252A4 (en) | Endoscope | |
| EP2856924A4 (en) | Endoscope | |
| GB201322435D0 (en) | Early Entry | |
| GB201214440D0 (en) | Kidney disease biomarker | |
| GB2500893B (en) | Spirometer | |
| GB2506845B (en) | Modified tubular | |
| GB201212069D0 (en) | Predicting resistance to disease | |
| GB201223223D0 (en) | Inflammatory bowel disease | |
| ZA201408522B (en) | Line design | |
| GB201309275D0 (en) | Early entry | |
| EP2543388A4 (en) | Drug for inflammatory bowel disease | |
| IL238769A0 (en) | Enemas | |
| GB201313844D0 (en) | No details | |
| GB201201805D0 (en) | Speculum | |
| EP2864414A4 (en) | Pvc-acrylate blends | |
| GB201308983D0 (en) | Early entry | |
| GB201020702D0 (en) | Inflammatory disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |